drugset / Trial / NCT03241173
A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01949 when given in combination with immune therapies in participants with advanced or metastatic malignancies.
Timeline
- Start
- 2017-10-09
- Primary completion
- 2019-09-17
- Completion
- 2019-09-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | INCAGN01949 | Monoclonal antibody | 70 mg | Intravenous |
| Subject | INCAGN01949 | Monoclonal antibody | 200 mg | Intravenous |
| Subject | INCAGN01949 | Monoclonal antibody | 350 mg | Intravenous |
| Subject | INCAGN01949 | Monoclonal antibody | 700 mg | Intravenous |
| Subject | Ipilimumab | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | 240 mg | Intravenous |